🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesSURPASS-CVOT: tirzepatide cardiovascular outcomes trial design — need advice Page 4

SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design — need advice

GenomicsKate Sat, Jan 3, 2026 at 11:59 AM 29 replies 1,587 viewsPage 4 of 6
BrianDallas92
Member
312
1,456
Oct 2024
Dallas, TX
Jan 12, 2026 at 2:27 AM#16
Dr.ObesityMed said:
Dose-response modeling for tirzepatide: Emax model fitting to the STEP/SURMOUNT dose-finding data shows: Semaglutide: ED50 ≈ 0.6mg, Emax ≈ -18%, Hill…

Second this.

Last edited: Jan 12, 2026 at 3:27 AM
44 17Dr.PathRoch, mona_PHX, andrew_nyc and 41 others
Reply Quote Save Share Report
anna.melb_AU
Member
678
2,890
Apr 2024
Melbourne, AU
Jan 13, 2026 at 5:10 AM#17

One thing that is still open after Dr.LipidDallas’s answer:

How much of the SELECT benefit is plausibly independent of the weight loss, and whether that distinction changes anything practical?

Last edited: Jan 13, 2026 at 9:10 AM
45 18paige_pharma, emma_london, tammy_FL and 42 others
Reply Quote Save Share Report
ben_calgary
Member
245
1,123
Oct 2024
Calgary, CA
Jan 14, 2026 at 7:53 AM#18
Dr.GutHealth said:
One practical note: write down what you did and when, before you need it.

I read this differently. The confidence in this thread is running ahead of the evidence, and I would rather the uncertainty were stated than smoothed over because it is unsatisfying.

Last edited: Jan 14, 2026 at 1:53 PM
46 19ZaraB_AL, JakeSmashed95, NauseaFreeNow and 43 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
lucas_SP_BR
Member
456
1,890
Jun 2024
São Paulo, BR
Jan 15, 2026 at 10:35 AM#19
Dr.GutHealth said:
One practical note: write down what you did and when, before you need it.

Correct as far as it goes. The part it does not cover is what to do when the honest answer is "not enough data", which is more often than anyone likes.

47 20KarenAZ_mom, zoe_NC, Dr.ObesityLA and 44 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Jan 16, 2026 at 1:17 PM#20

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part.

Last edited: Jan 16, 2026 at 5:17 PM
19 17PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 16 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register